胆固醇代谢物4β-基胆固醇作为肝脏CYP3A活性敏感内源生物标志物的应用,在PBPK框架内进行评估
Aneesh V Karkhanis1, Matthew D Harwood1, Felix Stader1
1Certara UK Limited, Certara Predictive Technologies, Level 2-Acero, 1 Concourse Way, Sheffield S1 2BJ, UK.
Pharmaceutics
|October 26, 2024
概括
一个新的基于生理学的药理动力学模型准确地模拟了由于CYP3A诱导导致的4β-基胆固醇 (4β-OHC) 水平升高. 这个经过验证的模型有助于评估肝脏CYP3A诱导的药物相互作用风险.
科学领域:
- 药理动力学 药理动力学
- 生物标志物开发 生物标志物开发
- 药物新陈代谢 药物新陈代谢
背景情况:
- 血4β-基胆固醇 (4β-OHC),一个胆固醇代谢物,随着CYP3A诱导物如利芬素的增加.
- 了解这些变化对于预测药物相互作用至关重要.
研究的目的:
- 为胆固醇和4β-OHC.开发和验证一种基于生理学的药理动力学 (PBPK) 模型.
- 模拟和预测由CYP3A诱导引起的4β-OHC变化.
主要方法:
- 使用Simcyp PBPK模拟器进行中出方法.
- 包含CYP3A和CYP27A的物理化学和代谢途径数据1.
- 根据基线验证了模型,并从不同人群的多项研究中诱导了4β-OHC水平.
主要成果:
- 该PBPK模型准确地预测了不同种族和性别特异性的基线4β-OHC水平.
- 该模型在里芬素治疗后成功回顾了增加的4β-OHC,证实了其模拟肝脏CYP3A诱导的能力.
- 在CYP3A4/5多态种群中以及与其他CYP3A诱导体验证模型性能.
结论:
- 为4β-OHC建立了一个经过验证,适合目的的PBPK模型.
- 这种建模框架可用于评估与肝脏CYP3A诱导相关的DDI风险.
- 该模型是对内源生物标志物和药物相互作用的未来研究的宝贵工具.
相关概念视频
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
32
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
32
Hepatic Drug Clearance: Effect of Protein Binding
161
Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
161
Hepatic Drug Clearance: Role of Transporters
41
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
41


